Biofrontera Inc. (BFRI)
Biofrontera Statistics
Share Statistics
Biofrontera has 8.87M shares outstanding. The number of shares has increased by 52.26% in one year.
Shares Outstanding | 8.87M |
Shares Change (YoY) | 52.26% |
Shares Change (QoQ) | 39.79% |
Owned by Institutions (%) | 0.74% |
Shares Floating | 7.33M |
Failed to Deliver (FTD) Shares | 35.52K |
FTD / Avg. Volume | 8.88% |
Short Selling Information
The latest short interest is 457.12K, so 5.15% of the outstanding shares have been sold short.
Short Interest | 457.12K |
Short % of Shares Out | 5.15% |
Short % of Float | 6.43% |
Short Ratio (days to cover) | 0.08 |
Valuation Ratios
The PE ratio is -338.58 and the forward PE ratio is -0.92. Biofrontera's PEG ratio is 3.39.
PE Ratio | -338.58 |
Forward PE | -0.92 |
PS Ratio | 161.19 |
Forward PS | 0.1 |
PB Ratio | 1356.37 |
P/FCF Ratio | -584.9 |
PEG Ratio | 3.39 |
Enterprise Valuation
Biofrontera Inc. has an Enterprise Value (EV) of 8.34M.
EV / Earnings | -0.47 |
EV / Sales | 0.22 |
EV / EBITDA | -0.48 |
EV / EBIT | -0.48 |
EV / FCF | -0.81 |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 1.11.
Current Ratio | 1.72 |
Quick Ratio | 1.17 |
Debt / Equity | 1.11 |
Total Debt / Capitalization | 52.61 |
Cash Flow / Debt | -2.09 |
Interest Coverage | -8.17 |
Financial Efficiency
Return on equity (ROE) is -4.01% and return on capital (ROIC) is -184.19%.
Return on Equity (ROE) | -4.01% |
Return on Assets (ROA) | -0.8% |
Return on Capital (ROIC) | -184.19% |
Revenue Per Employee | $405,467.39 |
Profits Per Employee | $-193,032.61 |
Employee Count | 92 |
Asset Turnover | 1.69 |
Inventory Turnover | 2.69 |
Taxes
Income Tax | 22K |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -44.81% in the last 52 weeks. The beta is 0.31, so Biofrontera's price volatility has been higher than the market average.
Beta | 0.31 |
52-Week Price Change | -44.81% |
50-Day Moving Average | 1.02 |
200-Day Moving Average | 1.04 |
Relative Strength Index (RSI) | 38.43 |
Average Volume (20 Days) | 399.77K |
Income Statement
In the last 12 months, Biofrontera had revenue of 37.3M and earned -17.76M in profits. Earnings per share was 0.
Revenue | 37.3M |
Gross Profit | 19.45M |
Operating Income | -17.21M |
Net Income | -17.76M |
EBITDA | -17.21M |
EBIT | -17.21M |
Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 5.91M in cash and 4.92M in debt, giving a net cash position of 983K.
Cash & Cash Equivalents | 5.91M |
Total Debt | 4.92M |
Net Cash | 983K |
Retained Earnings | -117.41M |
Total Assets | 22.1M |
Working Capital | 8.68M |
Cash Flow
In the last 12 months, operating cash flow was -10.27M and capital expenditures -10K, giving a free cash flow of -10.28M.
Operating Cash Flow | -10.27M |
Capital Expenditures | -10K |
Free Cash Flow | -10.28M |
FCF Per Share | 0 |
Margins
Gross margin is 52.14%, with operating and profit margins of -46.14% and -47.61%.
Gross Margin | 52.14% |
Operating Margin | -46.14% |
Pretax Margin | -47.55% |
Profit Margin | -47.61% |
EBITDA Margin | -46.14% |
EBIT Margin | -46.14% |
FCF Margin | -27.56% |
Dividends & Yields
BFRI does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 0% |
FCF Yield | -136.29% |
Analyst Forecast
The average price target for BFRI is $7, which is 723.5% higher than the current price. The consensus rating is "Buy".
Price Target | $7 |
Price Target Difference | 723.5% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 5, 2023. It was a backward split with a ratio of 1:20.
Last Split Date | Jul 5, 2023 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | -7.96 |
Piotroski F-Score | 4 |